| HUMAN-TRIAL | evidence | Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. | Retatrutide | Glycemic control · human-rct | 2026-06-13 |
| HUMAN-TRIAL | evidence | Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. | Retatrutide | Glycemic control · human-rct | 2025-12-01 |
| HUMAN-TRIAL | evidence | Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. | Retatrutide | human-observational | 2025-10-01 |
| HUMAN-TRIAL | evidence | Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. | Retatrutide | Glycemic control · human-rct · n = 189 | 2025-08-01 |
| HUMAN-TRIAL | evidence | Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. | Retatrutide | Weight & fat loss · human-rct | 2024-07-01 |
| HUMAN-TRIAL | evidence | Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. | Retatrutide | Glycemic control · human-rct | 2023-08-12 |
| HUMAN-TRIAL | evidence | Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. | LY3437943 | Weight & fat loss · human-rct | 2023-08-10 |
| HUMAN-TRIAL | evidence | LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. | LY3437943 | Weight & fat loss · human-rct · n = 72 | 2022-11-26 |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Participants With Type 2 Diabetes | LY-3437943 | Glycemic control · human-rct · n = 281 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | LY-3437943 | Glycemic control · human-rct · n = 64 | — |
| HUMAN-TRIAL | evidence | A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants | LY-3437943 | human-observational · n = 7 | — |
| HUMAN-TRIAL | evidence | A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | LY-3437943 | Weight & fat loss · human-observational · n = 32 | — |
| HUMAN-TRIAL | evidence | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | LY-3437943 | Glycemic control · human-rct · n = 1250 | — |
| HUMAN-TRIAL | evidence | Provide Pre-approval Expanded Access of LY3437943 | LY-3437943 | — | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | LY-3437943 | Weight & fat loss · human-rct · n = 586 | — |
| HUMAN-TRIAL | evidence | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | LY-3437943 | Liver health · human-rct · n = 4500 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | LY-3437943 | human-rct · n = 1946 | — |
| HUMAN-TRIAL | evidence | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | LY-3437943 | Glycemic control · human-rct · n = 537 | — |
| HUMAN-TRIAL | evidence | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | LY-3437943 | Glycemic control · human-rct · n = 80 | — |
| HUMAN-TRIAL | evidence | A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | LY-3437943 | Weight & fat loss · human-rct · n = 85 | — |
| HUMAN-TRIAL | evidence | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | LY-3437943 | n = 30 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | LY-3437943 | Weight & fat loss · human-rct · n = 445 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 2335 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 338 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | LY-3437943 | Glycemic control · human-rct · n = 72 | — |
| HUMAN-TRIAL | evidence | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | LY-3437943 | Glycemic control · human-rct · n = 320 | — |
| HUMAN-TRIAL | evidence | A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | LY-3437943 | human-rct · n = 45 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 32 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 1000 | — |
| HUMAN-TRIAL | evidence | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | LY-3437943 | Glycemic control · human-rct · n = 95 | — |
| HUMAN-TRIAL | evidence | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | LY-3437943 | Lipid & cardiovascular markers · human-rct · n = 10000 | — |
| HUMAN-TRIAL | evidence | Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 300 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 600 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | LY-3437943 | human-rct · n = 57 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | LY-3437943 | Weight & fat loss · human-observational · n = 46 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | LY-3437943 | Kidney function · human-observational · n = 29 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Healthy Participants With a High Body Mass Index | LY-3437943 | human-rct · n = 85 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | LY-3437943 | human-rct · n = 146 | — |
| HUMAN-TRIAL | evidence | A Study of LY3437943 in Participants With Impaired and Normal Liver Function | LY-3437943 | human-observational · n = 43 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | LY-3437943 | Weight & fat loss · human-rct · n = 250 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | LY-3437943 | Weight & fat loss · human-rct · n = 800 | — |
| HUMAN-TRIAL | evidence | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | LY-3437943 | Weight & fat loss · human-rct · n = 643 | — |
| REGULATORY | regulatory | D-0093-2026 — Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692 | FDA | — | 2025-07-30 |
| ANIMAL | evidence | GIPR:GCGR co-agonism restores normal weight in obese rodents. | Retatrutide | Weight & fat loss · animal | 2026-06-01 |
| ANIMAL | evidence | Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. | Retatrutide | Weight & fat loss · animal | 2026-06-01 |
| ANIMAL | evidence | Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation. | LY3437943 | Weight & fat loss · animal | 2026-05-19 |
| ANIMAL | evidence | Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. | Retatrutide | Addiction & substance use · animal | 2026-05-01 |
| ANIMAL | evidence | Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. | Retatrutide | Weight & fat loss · animal | 2026-04-01 |
| ANIMAL | evidence | Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. | Retatrutide | animal | 2025-12-01 |
| ANIMAL | evidence | Contractile effects of retatrutide in isolated mouse atrial preparations. | Retatrutide | Gut barrier & GI healing · animal | 2025-12-01 |